CU6 - ASX Charts, page-969

You need to note —

**Clarity Pharmaceuticals has been going for over 10years+ now. **

With an over 10 year view —
The trajectory looks overall painstaking and very gradual as the overall journey for Clarity Pharmaceuticals, before eventually listing publicly under CU6 ticker code about 4 years ago.(2020)

Then looking at listed history - see the shareprice shows a time of stabilising, was amply funded and continuing with advancing significant trials and research, while the market waited as work progressed.

But the market , main investors did not at all see or understand the forefront nature of Radiopharmaceuticals in oncology , or CU6 work as yet.

Then there was Telix awareness-initially also impacting to Clarity by about 2 years ago forwards, with also comprehension as well that CU6 copper isotopes diagnostics technology and ultimately treatment applications, were actually superior in many ways.

*Copper isotopes -better, safer, cheaper, & more generally avail longterm , and functionally much more workable and deliverable .

However CU6 was not yet at all really being seen,
or yet the recognition of CU6 and its own very important fundamentals.

Now, through over the past 12 mths and will be forwards, still occurring —emerging understanding & grudging even realisation even now belatedly that Clarity not to be dismissed or overlooked as ‘already run ‘ —
*And especially -

regarding the copper isotopes in radiopharma in which CU6 is focused.

*And also particularly -
Clarity’s unique developed through years dual receptor attachment ligand technology. *

CU6 ligand technology is imo best in world currently it seems - for the superior targeting ability to locate and attach to cancer cells and to remain at target cancer cells in most stable way currently, for lengthy time-

This is crucial for accuracy,+ also safest best cancer tumour detection;

and then obviously logical 1, 2 step next to use targeted treatments to follow in and kill the cancers.

With radiopharmaceutical agent of choice.

NB CU6 is also- also without nuclear radioisotopes, copper isotopes, though technologies including towards alpha treatment therapies where indicated, to deliver whichever best cancer lethal payloads to currently untreatable dire metastatic tumours cancer patients.

Not only the company, many valued research scientists have been here for over 10 years+ also, including the PhD medical scientist researcher MD.

Dr Alan Taylor aside from being eminently into sports and health, degrees in health & medical related sciences and then his PhD research especially wishing to impact cancer treatments and hope; had gone into investment banking through from the end of the 90s to post GFC.

Specifically he worked in raising capital for biomedical companies and research.

Funding having been so limited publicly & virtually unavailable here in Australia for compelling worthwhile and important targeted biomedical research.

Dr Taylor was then attracted very much by the potentials to really make a difference in research and development in radiopharmaceuticals, and went into what became Clarity Pharma, early in the last decade.

He returned to biomedical research & then has lead and been aboard Clarity Pharmaceuticals for this entire journey with the unique dual ligand technology carefully developed also in- company

To first be better than what is available, and make radiopharmaceuticals cancer diagnostics and treatments to be so much more robust , and not only better but also best.
As the aim in Clarity Pharmaceuticals.

CU6 copper isotope utilised technologies, developed to be with no1 accuracy, & above all to be safe or as safe as possible and not regressively harm also the patient— while saving lives more where now there hasn’t been real hope .

CU6 :

Best, safest, and cheap also, to be much more available as cancer therapies.

*More functional, accurate , lifesaving and life- preserving cancer diagnosis and treatments -

Better, safer and cheaper - where existing approved diagnosis methods do not even detect dire cancers at early tumours stage, let alone be able to treat satisfactorily.

***But to your point finally again, & to really ram it home for you:

CU6 only listed 4 years ago when was beneficial time to do so for the company stage, for ongoing development and commercialisation.

However Clarity has been going for more than a decade + with team and MD at the helm.

Careful development and evolution.

Stable good investors aboard throughout.

CU6 is not even valued at $2 billion usd.

*More has been paid by large pharmaceutical companies for less and way earlier stage than CU6 in radiopharmaceuticals, for technologies which have then failed at next phase at earlier stages research-

CU6 is through phase 2 with phase 3 appearing certain due to care in proving at every step.
In diagnositics.

And in treatment though at earlier stage phase 2 still, is undertaking also careful dose escalation in trials- which *Novartis with Pluvicto did not do *.

And with respect to competition and the overall field :

Radiopharmaceuticals has become the hottest field in oncology through recent years , and still gathering strength still as leading area in making a difference in metastatic and solid tumour cancers- the most dire& also sadly not uncommon.

eg. Prostate, breast, brain, organs cancers etc.

Pfizer wish to be no1 in oncology treatment by 2030 - and as yet : *do not have a standout candidate in radiopharmaceuticals*

*Radiopharmaceuticals is the no1 development area in oncology now —and copper isotopes are seen as the future in radiopharmaceuticals.*

ie. CU6, Clarity pharmaceuticals IP and assets & technologies in development.

*CU6 diagnostic is headed into phase 3 & is the worlds best - superior exponentially to current approved ( Telix & one other , which utilise nuclear isotopes , radiopharma )

Novartis Pluvicto is the only approved radiopharmaceutical treatment globally.

And only at present for prostate cancer.

—-They cannot access enough nuclear isotopes to fulfil the demand and need for these dire prostate cancer patients with spread tumours cancers, locally even in the US.

(Of course- only tumours that have also been detected , with existing approved diagnostics , calls being great to improve access for radiopharmaceuticals diagnosis, Telix notably.
Telix the preferred of only 2 existing diagnostic agents radiopharmaceuticals, both using generic I think nuclear isotope technologies, and also only approved - Only for prostate cancer yet. )

Currently due to very short half life of nuclear isotopes with both the only approved diagnostics and treatment agents-can only be in a short window of time after location constrained production of the isotopes needed.

—Expensive.

—Sensitive nuclear radiation particles.

CU6 developing copper isotope treatment- also way way superior with results in clearing cancer completely even, compared to the current only approved radiopharmaceutical treatment, Novartis Pluvicto, which is also only specifically for prostate cancer.

With significant collateral harm also from Pluvicto as well as its short harsh time of action .

Life saving or life giving treatment though being for many men only atm

LOTS of practical and functional issues with current only approved radiopharmaceutical treatment, Novartis Pluvicto, and only approved as yet in prostate cancer. Though they are first approved therapy.

Acute global gallium shortage can be solved with time and government policy - but is not un- extreme overall.

—Expensive,

—-more dangerous or harmful,

—-constrained where can be utilised.

Fundamentally extremely short half life of nuclear radiopharmaceutical agents

CU6- in development, utilising copper isotopes,

—-Better, safer, cheaper, much more functionally adaptive for ongoing longterm production of needed isotopes and distribution.

——And also much safer and cheaper as copper isotopes have a shelf life, and also not focused or wed to nuclear radioactive particles.

Novartis are not interested in being in the diagnostic space in oncology.

Absolutely accurate diagnosis however needed for their treatment to be prescribed, and at present only one cancer and late stage practically where pluvicto being used due to how is at present , & only approved for prostate cancer..

Meanwhile—
Clarity pharmaceuticals treatment way superior to date.
Other companies also are going more into copper isotope utilisation— though without benefit of Clarity pharmaceuticals over decade long development and advancement and proving inc safety ;
but also especially Cu6 dual ligand delivery technology-
Copper isotopes surely being indicated for the future much more.

Esp for globally.

What do you surmise might happen ?